Literature DB >> 30384366

Shengmai San Alleviates Diabetic Cardiomyopathy Through Improvement of Mitochondrial Lipid Metabolic Disorder.

Jing Tian1, Wenzhu Tang1, Ming Xu2, Chen Zhang1, Pei Zhao3, Tongtong Cao3, Xiaoli Shan3, Rong Lu1, Wei Guo4.   

Abstract

BACKGROUND/AIMS: Shengmai San (SMS), prepared from Panax ginseng, Ophiopogon japonicus, and Schisandra chinensisin, has been widely used to treat ischemic disease. In this study, we investigated whether SMS may exert a beneficial effect in diabetic cardiomyopathy through improvement of mitochondrial lipid metabolism.
METHODS: A leptin receptor-deficient db/db mouse model was utilized, and lean age-matched C57BLKS mice served as non-diabetic controls. Glucose and lipid profiles, myocardial structure, dimension, and function, and heart weight to tibial length ratio were determined. Myocardial ultrastructural morphology was observed with transmission electron microscopy. Protein expression and activity of oxidative phosphorylation (OXPHOS) complex were assessed using western blotting and microplate assay kits. We also observed cellular viability, mitochondrial membrane potential, OXPHOS complex activity, and cellular ATP level in palmitic acid-stimulated H9C2 cardiomyocytes. Changes in the sirtuin (SIRT1)/AMP-activated protein kinase (AMPK)/peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) pathway and mitochondrial uncoupling signaling were assessed using western blotting and quantitative real-time PCR.
RESULTS: Leptin receptor-deficient db/db mice exhibit obesity, hyperglycemia, and hyperlipidemia, accompanied by distinct myocardial hypertrophy and diastolic dysfunction. SMS at a dose of 3 g/kg body weight contributed to a recovery of diabetes-induced myocardial hypertrophy and diastolic dysfunction. SMS administration led to an effective restoration of mitochondrial structure and function both in vivo and in vitro. Furthermore, SMS markedly enhanced SIRT1 and p-AMPKα protein levels and decreased the expression of acetylated-PGC-1α and uncoupling protein 2 protein. SMS also restored the depletion of NRF1 and TFAM levels in diabetic hearts and H9C2 cardiomyocytes.
CONCLUSION: The results indicate that SMS may alleviate diabetes-induced myocardial hypertrophy and diastolic dysfunction by improving mitochondrial lipid metabolism.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Diabetic cardiomyopathy; Mice; Mitochondria; Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; Shengmai San

Mesh:

Substances:

Year:  2018        PMID: 30384366     DOI: 10.1159/000494791

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  5 in total

1.  Use of a Systematic Pharmacological Methodology to Explore the Mechanism of Shengmai Powder in Treating Diabetic Cardiomyopathy.

Authors:  Shi-Ying Zhang; Kai-Lin Yang; Zhi-Yong Long; Wei-Qing Li; Hui-Yong Huang
Journal:  Med Sci Monit       Date:  2020-02-05

2.  ShengMai-San Attenuates Cardiac Remodeling in Diabetic Rats by Inhibiting NOX-Mediated Oxidative Stress.

Authors:  Yanting Lu; Shu Zhu; Xiaoyan Wang; Juhai Liu; Yingying Li; Wei Wang; Shijun Wang; Furong Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-02-11       Impact factor: 3.168

Review 3.  The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19.

Authors:  Xuedong An; Liyun Duan; Yue Hong Zhang; Shenghui Zhao; Rong Rong Zhou; Yingying Duan; Fengmei Lian; Xiaolin Tong
Journal:  Chin Med       Date:  2021-06-07       Impact factor: 5.455

4.  Chemical Variations among Shengmaisan-Based TCM Patent Drugs by Ultra-High Performance Liquid Chromatography Coupled with Hybrid Quadrupole Orbitrap Mass Spectrometry.

Authors:  Lulu Xu; Zhanpeng Shang; Yungang Tian; Ming Xiong; Dilaram Nijat; Yuan Wang; Xue Qiao; Min Ye
Journal:  Molecules       Date:  2021-06-30       Impact factor: 4.411

Review 5.  Remedying the Mitochondria to Cure Human Diseases by Natural Products.

Authors:  Jian-Kang Mu; Yan-Qin Li; Ting-Ting Shi; Li-Ping Yu; Ya-Qin Yang; Wen Gu; Jing-Ping Li; Jie Yu; Xing-Xin Yang
Journal:  Oxid Med Cell Longev       Date:  2020-07-13       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.